Mounjaro can reduce absorption of birth control pills, report warns of unintended pregnancies

Mounjaro, an injectable drug used to treat type 2 diabetes and to help with weight loss, can reduce how much of an oral contraceptive pill the body absorbs, and its label carries a warning about that interaction, according to reporting from CBS Boston ^[1].

The report described unintended pregnancies in some patients who were taking Mounjaro together with oral birth control. It said the drug can reduce absorption of "the pill" in the gut and that the label suggests people using oral contraception switch to a non-oral birth control method. It also said many doctors may not be counseling patients about that warning ^[1].

The report did not say how many unplanned pregnancies were involved, how much the drug lowers absorption, or how often the interaction leads to contraceptive failure ^[1]. Mounjaro contains tirzepatide. The report did not address whether Zepbound, the weight-loss brand of the same medicine, carries the same label language, and it did not say whether Ozempic and Wegovy, which contain semaglutide, do either ^[1].

Doctors interviewed for the report gave different timing advice. Some recommend spacing the injection and the pill at least one hour apart. Others say patients who want to avoid pregnancy should start using condoms several weeks before starting any of these weight-loss drugs ^[1].

Two things remain unclear. It is not known whether other hormonal birth control methods, such as the patch, are affected, and it is not known whether similar medications, including Ozempic and Wegovy, carry the same risk ^[1]. Because millions of people take these injectable drugs for weight loss or blood sugar control, the question touches a large group of patients ^[1].

Why it matters for patients

For anyone using Mounjaro and an oral contraceptive at the same time, the report raises the possibility that the pill may not work as expected ^[1]. The label's suggested response is a change in birth control method, not in the diabetes or weight-loss drug: it advises a non-oral contraceptive for people on the pill ^[1]. Some doctors cited in the report take a different approach, recommending condoms starting several weeks before treatment begins ^[1].

The report suggests the warning is not always passed along in the clinic, saying many doctors may not be counseling patients accordingly ^[1]. That means whether a patient hears about the interaction may depend on the prescriber, though the report does not quantify how often counseling happens or is missed ^[1].

Patients who take Mounjaro and rely on birth control also face gaps in information. The report does not say whether the patch, the ring or hormonal implants are affected, and it does not say whether the same issue applies to Ozempic and Wegovy ^[1]. Those questions have not been answered in the reporting.

For readers weighing these drugs, the questions the report raises — which contraceptive method is being used, whether the prescriber has discussed the interaction, and whether a backup method is in place — are ones patients can raise with their own clinicians ^[1].